University of Birmingham: Drug Could More Effectively Treat Patients Hospitalised With COVID-19 Pneumonia, Early Stage Research Finds
December 17, 2021
December 17, 2021
BIRMINGHAM, England, Dec. 17 (TNSJou) -- The University of Birmingham issued the following news release on Dec. 16, 2021:
A proof-of-concept trial led by the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust has identified a drug that may offer benefit some patients hospitalised with COVID-19 pneumonia.
The CATALYST trial tested UK-based bio-pharmaceutical company Izana Bioscience's namilumab (IZN-101) as a potential therapeutic to t . . .
A proof-of-concept trial led by the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust has identified a drug that may offer benefit some patients hospitalised with COVID-19 pneumonia.
The CATALYST trial tested UK-based bio-pharmaceutical company Izana Bioscience's namilumab (IZN-101) as a potential therapeutic to t . . .